{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:10:25Z","timestamp":1793823025959,"version":"4.6.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Equity Health"],"DOI":"10.1186\/s12939-025-02610-3","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:08:45Z","timestamp":1760450925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dollars and dilemmas: lenacapavir\u2019s pricing, patents, and the path to affordability"],"prefix":"10.1186","volume":"24","author":[{"given":"Victor Abiola","family":"Adepoju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrakib","family":"Abdulrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"2610_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12939-024-02346-6","volume":"23","author":"S Alageel","year":"2024","unstructured":"Alageel S, Alsadhan NM, Alkhaldi G, Alkasabi R, Alomair N. Public perceptions of HIV\/AIDS awareness in the Gulf Council Cooperation countries: a qualitative study. Int J Equity Health. 2024;23:269. https:\/\/doi.org\/10.1186\/s12939-024-02346-6.","journal-title":"Int J Equity Health"},{"key":"2610_CR2","unstructured":"The Guardian. \u2018HIV-ending\u2019 drug could be made for just $25 per patient a year, say researchers | Aids and HIV 2025. https:\/\/www.theguardian.com\/society\/2025\/jun\/17\/hiv-ending-drug-lenacapavir-manufacture-cost-per-patient-gilead (accessed June 22, 2025)."},{"key":"2610_CR3","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","volume":"392","author":"CF Kelley","year":"2025","unstructured":"Kelley CF, Acevedo-Qui\u00f1ones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, et al. Twice-Yearly Lenacapavir for HIV prevention in men and Gender-Diverse persons. N Engl J Med. 2025;392:1261\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2411858.","journal-title":"N Engl J Med"},{"key":"2610_CR4","doi-asserted-by":"publisher","first-page":"100642","DOI":"10.1016\/j.lana.2023.100642","volume":"28","author":"TS Torres","year":"2023","unstructured":"Torres TS, Teixeira SLM, Hoagland B, Konda KA, Derrico M, Moreira RI, et al. Recent HIV infection and annualized HIV incidence rates among sexual and gender minorities in Brazil and Peru (ImPrEP Seroincidence study): a cross-sectional, multicenter study. Lancet Reg Health - Am. 2023;28:100642. https:\/\/doi.org\/10.1016\/j.lana.2023.100642.","journal-title":"Lancet Reg Health - Am"},{"key":"2610_CR5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.2105\/ajph.2009.186288","volume":"100","author":"OS Onyeabor","year":"2010","unstructured":"Onyeabor OS. Ethical imperative of posttrial access to antiretroviral treatment. Am J Public Health. 2010;100:966\u20137. https:\/\/doi.org\/10.2105\/ajph.2009.186288.","journal-title":"Am J Public Health"},{"key":"2610_CR6","unstructured":"Gilead. Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six. Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries 2024. https:\/\/investors.gilead.com\/news\/news-details\/2024\/Gilead-Signs-Royalty-Free-Voluntary-Licensing-Agreements-With-Six-Generic-Manufacturers-to-Increase-Access-to-Lenacapavir-for-HIV-Prevention-in-High-Incidence-Resource-Limited-Countries\/default.aspx (accessed June 21, 2025)."},{"key":"2610_CR7","unstructured":"The Global Fund, Global Fund. accessed June 22, PEPFAR Announce Coordinated Effort to Reach 2 Million People with Lenacapavir for PrEP to Significantly Reduce Global HIV Infections 2024. https:\/\/www.theglobalfund.org\/en\/news\/2024\/2024-12-17-global-fund-pepfar-coordinated-effort-2-million-people-lenacapavir-prep\/ (2025)."},{"key":"2610_CR8","unstructured":"Salud por Derecho. Lenacapavir: Gilead\u2019s voluntary licenses do not reach countries that need them 2024. https:\/\/saludporderecho.org\/en\/lenacapavir-las-licencias-voluntarias-de-gilead-no-llegan-a-paises-que-las-necesitan\/ (accessed June 21, 2025)."},{"key":"2610_CR9","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","volume":"391","author":"L-G Bekker","year":"2024","unstructured":"Bekker L-G, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, et al. Twice-Yearly Lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391:1179\u201392. https:\/\/doi.org\/10.1056\/NEJMoa2407001.","journal-title":"N Engl J Med"},{"key":"2610_CR10","doi-asserted-by":"publisher","first-page":"1079990","DOI":"10.3389\/fpubh.2023.1079990","volume":"11","author":"E Moyo","year":"2023","unstructured":"Moyo E, Moyo P, Murewanhema G, Mhango M, Chitungo I, Dzinamarira T. Key populations and Sub-Saharan africa\u2019s HIV response. Front Public Health. 2023;11:1079990. https:\/\/doi.org\/10.3389\/fpubh.2023.1079990.","journal-title":"Front Public Health"},{"key":"2610_CR11","unstructured":"Hoen E, \u2019t. FDA approval of injectable lenacapavir for Pre-Exposure Prophylaxis (PrEP) opens the road to ending HIV | Medicines Law & Policy. 2025. https:\/\/medicineslawandpolicy.org\/2025\/06\/fda-approval-of-injectable-lenacapavir-for-pre-exposure-prophylaxis-prep-opens-the-road-to-ending-hiv\/ (accessed June 22, 2025)."},{"key":"2610_CR12","doi-asserted-by":"publisher","first-page":"e765","DOI":"10.1016\/S2352-3018(24)00239-X","volume":"11","author":"L Wu","year":"2024","unstructured":"Wu L, Kaftan D, Wittenauer R, Arrouzet C, Patel N, Saravis AL, et al. Health impact, budget impact, and price threshold for cost-effectiveness of Lenacapavir for HIV pre-exposure prophylaxis in Eastern and Southern africa: a modelling analysis. Lancet HIV. 2024;11:e765\u201373. https:\/\/doi.org\/10.1016\/S2352-3018(24)00239-X.","journal-title":"Lancet HIV"}],"container-title":["International Journal for Equity in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12939-025-02610-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12939-025-02610-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12939-025-02610-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T01:03:40Z","timestamp":1760490220000},"score":1,"resource":{"primary":{"URL":"https:\/\/equityhealthj.biomedcentral.com\/articles\/10.1186\/s12939-025-02610-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2610"],"URL":"https:\/\/doi.org\/10.1186\/s12939-025-02610-3","relation":{},"ISSN":["1475-9276"],"issn-type":[{"value":"1475-9276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"22 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"270"}}